Investing Profile

Rob Hopfner

InvestorVC
Managing Partner at Pivotal bioVenture Partners
pivotalbiovp.com/team-members...San Francisco, California
Photo of Rob Hopfner, Managing Partner at Pivotal bioVenture Partners

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
$100K - $5.0M
$1.5M
13
$300M
CompanyStageDateRound SizeTotal Raised
Evommune
Series BApr 2023$50M
Series ASep 2021$83M
SeedNov 2020$13M
$150M
Co-investors: Ash Khanna (Pivotal bioVenture Partners), Mark Chin (Arix Bioscience)
Oculis
Post Ipo EquityMar 2023$91M
Series CMay 2021$57M
Series BJan 2018$21M
$170M
Co-investors: Zhi Yang (BVCF (Bioveda China Fund)), Lionel Carnot (Earlybird Venture Capital), Florent Gros (Earlybird Venture Capital)
Plexium
Series BFeb 2022$100M
Series AJan 2021$35M
$140M
Co-investors: Kiersten Stead (DCVC (Data Collective)), Adam Goulburn (Lux Capital Management), Tim Kutzkey (The Column Group)
Rallybio
Series BApr 2020$150M
$180M
Co-investors: Tim Shannon (Canaan Partners)
Inozyme
Series AApr 2019$67M
$67M
Co-investors: Sarah Bhagat (Sofinnova Investments)
Civitas Therapeutics
Series CAug 2014$55M
Series BSep 2013$38M
$110M
Co-investors: Tim Shannon (Canaan Partners)
Hyperion Therapeutics
Series CJun 2009$60M
$100M
Co-investors: James Healy (Sofinnova Investments), Jake Nunn (SR One Capital Management)